This week, GW Pharmaceuticals (NASDAQ: GWPH) had an advisory committee meeting regarding its epilepsy drug Epidiolex, and the results were exciting for both the drug itself and the U.S. medical marijuana industry at large.In this week's episode of Industry Focus: Healthcare, analyst Kristine Harjes and Motley Fool contributor Shannon Jones explain why the results were so promising, what this could mean for the future of medical marijuana, and a few important things investors need to know about GW before diving in.Also, they take a look at Biogen's (NASDAQ: BIIB) recent deal with Ionis (NASDAQ: IONS).